Emtricitabine/Tenofov Alafenam
Brand name: Descovy
Rank #81 of 500 drugs by total cost
$222.4M
Total Cost
94,580
Total Claims
$222.4M
Total Cost
2,294
Prescribers
$2,352
Cost per Claim
6,576
Beneficiaries
98,736
30-Day Fills
$97K
Avg Cost/Provider
41
Avg Claims/Provider
About Emtricitabine/Tenofov Alafenam
Emtricitabine/Tenofov Alafenam (sold as Descovy) was prescribed 94,580 times by 2,294 Medicare Part D providers in 2023, costing the program $222.4M. At $2,352 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 78 | Abacavir/Dolutegravir/Lamivudi (Triumeq) | $238.1M | 61,147 |
| 79 | Riociguat (Adempas) | $236.6M | 17,620 |
| 80 | Elviteg/Cob/Emtri/Tenof Alafen (Genvoya) | $236.5M | 56,626 |
| 81 | Emtricitabine/Tenofov Alafenam (Descovy) | $222.4M | 94,580 |
| 82 | Immun Glob G(Igg)/Gly/Iga Ov50 (Gammagard Liquid) | $222.1M | 22,768 |
| 83 | Immun Glob G(Igg)/Pro/Iga 0-50 (Hizentra) | $222.0M | 21,722 |
| 84 | Pimavanserin Tartrate (Nuplazid) | $219.0M | 51,053 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology